Pharmaceutical Sales Force Strategies

Driving ROI through best practice in targeting, management, outsourcing and technologies

By Steven Seget

Table of Contents
# Table of Contents

## Pharmaceutical Sales Force Strategies

### Executive summary 10

Pharmaceutical sales force landscape 10  
Sizing, structuring and targeting 11  
Recruiting, training and rewarding 12  
Enabling technologies 13  
Outsourcing and partnering 13  
Strategies for increasing promotional ROI 15

### Chapter 1  Pharmaceutical sales force landscape 18

Summary 18  
Introduction 19  
Changing dynamics of the pharmaceutical industry 19  
Resistors to pharmaceutical sales growth 19  
Cost containment 20  
Generic competition and parallel importing 21  
R&D costs and productivity 22  
M&A activity 25  
Rising commercial expenses 26  
Physician detailing 27  
Commercial ROI 28  
Physician detailing ROI 35  
Changing needs of the physician 35  
Detailing trends 36  
A quieter voice in a louder market 39  
Content not frequency 40  
The PhRMA code of conduct 41  
Impact on the shape and role of the pharmaceutical sales force 42  
Organization 43  
Management 43  
Technologies 44
Chapter 2  Sizing, structuring and targeting  46

Summary  46
Introduction  47
Sales force numbers  49
Trends in headcount  50
US sales force numbers  52
European sales force numbers  54
Japanese sales force numbers  54
Case study: Pfizer  55
Sales force structures  57
Trends in structure  57
US sales force structures  58
European sales force structures  59
Japanese sales force structures  61
Segmenting and targeting  62
Product prioritization  62
Primary care versus specialty  63

Chapter 3  Recruiting, training and rewarding  65

Summary  65
Introduction  66
Recruiting talent  66
Internal versus external HR  67
Training and development  69
Benchmarking detailing performance  70
Training versus coaching  71
Case study: AstraZeneca  72
Incentives and rewards  74
Trends in remuneration structure  74
Incentive programs  78
Non-cash incentives  80

Chapter 4  Enabling technologies  83

Summary  83
Measuring ROI 125
Field force productivity 125
Sales force ROI 127
  Organization 130
  Management 131
  Technology 132
  Partnering 134
CRM 136
Physician’s perceptions 137
Lasting physician relationships 138
Partnering with the patient 139
Best practices 140
Meetings and events 140
Mid-level practitioners 141
Permission-based sales model 142
Case study: Pharma’s top-ranked sales force 143

Appendix 146

Primary research 146
References 148
Index 152
List of Figures

Figure 1.1: Resistors to pharmaceutical revenue growth 20
Figure 1.2: R&D expenditure as a proportion of sales, 1980-2003 24
Figure 1.3: R&D productivity, 1994-2003 25
Figure 1.4: Absolute and proportional promotional expenses, 2000-2003 26
Figure 1.5: Promotional expenses split by source, 2000-2003 27
Figure 1.6: Commercial ROI by leading pharma company, 2002-2003 30
Figure 1.7: Commercial ROI by leading biotech company, 2002-2003 32
Figure 1.8: Commercial ROI by leading specialty company, 2002-2003 34
Figure 1.9: Trends in the number of detailing visits per sales rep over next 2-3 years 37
Figure 1.10: Trends in the average length of detailing visits over next 2-3 years 39
Figure 1.11: Key influences on sales force ROI 42
Figure 2.12: Impact of US promotional spend on US sales, 2003 47
Figure 2.13: Impact of US detailing spend on US sales, 2003 48
Figure 2.14: Impact of US sales force size on US detailing spend, 2003 50
Figure 2.15: Trends in sales force headcount over next 2-3 years 52
Figure 2.16: Impact of US sales force size on US sales, 2003 53
Figure 2.17: Typical US sales force structure, 2003 59
Figure 2.18: Typical EU sales force structure, 2003 60
Figure 2.19: Typical Japanese sales force structure, 2003 61
Figure 3.20: Trends in the proportion of sales force remuneration comprised of basic pay over next 2-3 years 77
Figure 4.21: Greatest impact on sales force effectiveness over next 2-3 years 89
Figure 4.22: Uptake of eDetailing across Europe and the US 95
Figure 5.23: Trends in the use of CSOs over next 2-3 years 110
Figure 5.24: Trends in the use of collaborative sales forces over next 2-3 years 118
Figure 6.25: Field force productivity model 127
Figure 6.26: Sales force ROI model 128
Figure 6.27: Relative ROI impact of sales force effectiveness strategies 129
Figure 6.28: Survey respondents split by company type and region 148

List of Tables

Table 1.1: Total pharmaceutical R&D expenditure, 1980-2003 22